The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial

The PREVENT IV data will establish whether VG pretreatment with an E2F transcription factor decoy, edifoligide, can improve graft patency and reduce the long-term morbidity and mortality of patients undergoing CABG surgery.